LearnDrugs.com
Oncology

Antineoplastic / Chemotherapy Overview

High-yield High-alert Verified · Jul 2026

One framework for all of chemotherapy — target the fastest-dividing cells, and manage the collateral damage to the patient’s own fast-dividing tissues.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 The core idea — and the core problem

Cancer is uncontrolled cell division. Traditional (cytotoxic) chemotherapy exploits that by poisoning cells that divide rapidly — damaging DNA, blocking its synthesis, or disrupting the machinery of mitosis. Because cancer cells divide fast, they take the biggest hit.

But the body has its own fast-dividing normal tissues, and chemotherapy cannot tell them apart. This single fact explains almost every classic chemo side effect: the bone marrow (blood cells), the GI mucosa (mouth-to-gut lining), and the hair follicles all divide quickly, so they are collateral damage. The whole of chemotherapy nursing follows from anticipating that damage.

Chemo kills fast-dividing cells — cancer, but also marrow, gut lining, and hair follicles (the classic toxicities).

02 Myelosuppression and the nadir — the dose-limiting toxicity

The most dangerous common toxicity is myelosuppression — the marrow stops making blood cells. It falls to its lowest point, the nadir, roughly 7–14 days after a dose, then recovers before the next cycle. The three cell lines fail with three consequences: neutropenia → life-threatening infection (a fever in a neutropenic patient is an emergency), thrombocytopenia → bleeding, and anemia → fatigue.

This is where chemotherapy connects to the supportive drugs already in this course: colony-stimulating factors like filgrastim (Hematologic system) rebuild neutrophils, erythropoiesis-stimulating agents treat anemia, and antiemetics (Digestive system) — including the 5-HT3 "-setrons" — control the nausea. Nursing care centers on neutropenic precautions, monitoring the CBC around the nadir, and treating neutropenic fever immediately.

Blood counts fall to a nadir ~7–14 days after chemo: neutropenia→infection, thrombocytopenia→bleeding, anemia→fatigue.

03 Three more must-knows: hazardous handling, extravasation, tumor lysis

Hazardous-drug handling. Antineoplastics are hazardous to the people who give them (mutagenic/carcinogenic). Nurses follow USP <800> precautions — chemotherapy-rated gloves and gown, closed-system transfer devices, and dedicated spill kits — and dispose of drug and body fluids as hazardous waste.

Extravasation. Many agents are vesicants — if they leak out of the vein into tissue they cause severe necrosis. The response is to stop the infusion immediately, leave the catheter, aspirate, and follow the drug-specific antidote protocol. Two lethal-error safety rules stand out: doxorubicin (a vesicant) carries cumulative, dose-dependent cardiotoxicity (heart failure past ~550 mg/m²), and vincristine is FATAL if given intrathecally — it must only ever be given IV. Tumor lysis syndrome (TLS) is the third emergency: rapid tumor cell breakdown floods the blood with potassium, phosphate, and uric acid (hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia), risking acute kidney injury and arrhythmias — prevented with hydration and allopurinol/rasburicase.

Three chemo emergencies: handle as hazardous; stop infusion for vesicant extravasation; hydrate/treat tumor lysis syndrome.

Drug names

Generic Brand
cyclophosphamide Cytoxan — alkylating agent
doxorubicin Adriamycin — antitumor antibiotic
vincristine Oncovin — vinca alkaloid
cisplatin Platinol — platinum agent
methotrexate — antimetabolite (see Immune)

Indications

  • Curative, adjuvant, neoadjuvant, or palliative treatment of malignancy
  • Hematologic cancers (leukemia, lymphoma) and solid tumors
  • Often combination regimens to hit different cell-cycle phases and limit resistance

Mechanism of action

Cytotoxic antineoplastics kill dividing cells by damaging or blocking DNA/RNA synthesis and mitosis: alkylating agents (cyclophosphamide) cross-link DNA; antimetabolites (methotrexate, 5-fluorouracil) block nucleotide synthesis; antitumor antibiotics (doxorubicin) intercalate DNA and inhibit topoisomerase; vinca alkaloids (vincristine) and taxanes disrupt the mitotic spindle; platinum agents (cisplatin) cross-link DNA. Cell-cycle–specific agents act in one phase; non-specific agents act throughout.

In plain terms
These drugs poison cells while they divide — hitting fast-growing cancer hardest, but also the body’s own fast-growing tissues.

Therapeutic effects — what you'll see working

Success is tumor response (shrinkage, remission, or cure) balanced against toxicity. Doses are timed in cycles to let normal marrow recover between hits — the reason the nadir and count recovery drive scheduling.

Tumor cell kill Remission / disease control
Tumor cell kill
Damaging DNA or mitosis in dividing cells shrinks tumors and, in curable cancers, eradicates them.
Remission / disease control
Cyclic therapy drives and maintains remission, or palliates symptoms and prolongs life in advanced disease.

Adverse effects

The toxicities are predictable from the mechanism — damage to the fastest-dividing normal tissues — plus agent-specific organ toxicities and the handling/administration emergencies.

Black-box warning — most severe: ■ Boxed warnings — agent-specific (examples) Hold & notify
Doxorubicin: cumulative, dose-dependent cardiotoxicity/heart failure and severe tissue necrosis on extravasation. Vincristine: FATAL if given intrathecally (IV use only). Many agents: severe myelosuppression; must be given by clinicians experienced in cytotoxic therapy.
Track the cumulative anthracycline dose (heart failure risk past ~550 mg/m²), and enforce the "vincristine IV only" rule with distinct labeling/packaging — intrathecal administration is uniformly fatal.
Warning: Serious — myelosuppression Report immediately
Neutropenia (→ neutropenic fever/sepsis — an emergency), thrombocytopenia (→ bleeding), anemia; counts lowest at the nadir ~7–14 days.
Monitor the CBC around the nadir; institute neutropenic precautions; treat fever in a neutropenic patient as an emergency with prompt cultures and antibiotics. Support with CSFs/ESAs as indicated.
Warning: Serious — tumor lysis syndrome & organ toxicities
TLS: hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia → AKI/arrhythmia (bulky/rapidly proliferating tumors). Agent-specific: cisplatin nephro/ototoxicity, cyclophosphamide hemorrhagic cystitis (mesna), vincristine peripheral neuropathy.
Prevent TLS with aggressive hydration and allopurinol or rasburicase and monitor electrolytes/renal function. Give mesna and hydration with high-dose cyclophosphamide; assess for neuropathy with vinca alkaloids.
Caution: Common
Nausea/vomiting, mucositis/stomatitis, diarrhea, alopecia, fatigue; injection-site and infusion reactions.
Premedicate with antiemetics (5-HT3 antagonists, dexamethasone, ± NK1 antagonists); provide oral care for mucositis; reassure that alopecia is usually reversible.

Contraindications

Cytotoxic therapy is deferred or dose-reduced where marrow/organ reserve or pregnancy makes it unsafe; these are relative and regimen-specific.

Severe pre-existing myelosuppression / active uncontrolled infection use caution
Further marrow suppression can be fatal; treatment is usually held until counts recover and infection is controlled.
Pregnancy, especially first trimester use caution
Many antineoplastics are teratogenic/mutagenic; effective contraception is required during and after therapy.
Significant organ dysfunction relevant to the agent (cardiac for anthracyclines, renal for cisplatin/methotrexate) use caution
Reduced organ reserve raises the risk of the agent’s specific toxicity and impairs clearance.
Intrathecal route for vincristine / non-IV routes for IV-only agents
Intrathecal vincristine is uniformly fatal; route errors with cytotoxics cause catastrophic harm.

When to hold

Assess before giving — these findings mean hold the dose and act.

Nadir / myelosuppression (counts lowest ~7–14 days after a dose)
Institute neutropenic precautions, monitor the CBC, and treat neutropenic fever as an emergency.
Vesicant extravasation (drug leaking from the vein into tissue)
Stop the infusion immediately, leave the catheter in place, aspirate, and follow the drug-specific antidote protocol.
Tumor lysis syndrome (bulky / rapidly proliferating tumors)
Prevent with aggressive hydration and allopurinol/rasburicase; monitor potassium, phosphate, uric acid, and renal function.
Hazardous-drug handling (USP <800>)
Wear chemo-rated gloves/gown, use closed-system transfer devices, and dispose of drug and body fluids as hazardous waste.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Safe handling & administration
Follow USP <800> hazardous-drug precautions: chemo-rated gloves/gown, closed-system transfer devices, and hazardous-waste disposal of drug and body fluids.
Why: Antineoplastics are mutagenic/carcinogenic to staff; engineering controls and PPE protect the caregiver.
Verify orders with an independent double-check, confirm the route (e.g., vincristine IV only), and monitor the IV site continuously for extravasation — stop the infusion at once if it occurs.
Why: Route and dosing errors with cytotoxics are catastrophic, and vesicant extravasation causes severe tissue necrosis.
Monitoring & supportive care
Monitor CBC around the nadir, institute neutropenic precautions, and treat neutropenic fever as an emergency.
Why: Myelosuppression is the dose-limiting toxicity; infection in a neutropenic patient can progress to sepsis within hours.
Prevent tumor lysis syndrome with hydration and allopurinol/rasburicase in high-risk tumors; premedicate with antiemetics and provide oral care.
Why: TLS causes life-threatening electrolyte shifts and AKI; antiemetics and mouth care manage the predictable GI toxicities.
Teach infection-avoidance, bleeding precautions, and that hair loss is usually temporary; provide fertility and contraception counseling.
Why: Empowers self-monitoring during the nadir and addresses the psychosocial and reproductive impact of therapy.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.